Latest Breaking News On - Us biomedical advanced research - Page 5 : comparemela.com

Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens dur

United statesNew south walesJames grahamAndrew geddesJohn prendergastAlanw duntonMichael fitzhughHannah tsunemotoMichele diliziaUs department of defenseInternational conventionAmerican society for clinical pharmacologyDrug administrationDevelopment authorityRecce pharmaceuticals ltdBiomedical advanced research